Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.

Alexander HendricksPhilip RosenstielSebastian HinzGreta BurmeisterChristoph RöckenKathrin BoerschClemens SchafmayerThomas BeckerAndre FrankeMichael Forster

Published in: BMC medical genetics (2020)

As FOLFIRI+Bevacizumab has recently also been associated with sustained complete remission in a APC/TP53/KRAS triple-mutated patient, these driver genes should be tested and monitored in a more in-depth manner in future patients. Patients with metastatic disease should be monitored more closely during and after chemotherapy, ideally using cfDNA.

Keyphrases

wild type
metastatic colorectal cancer
end stage renal disease
ejection fraction
locally advanced
newly diagnosed
squamous cell carcinoma
case report
gene expression
ionic liquid
ultrasound guided
disease activity
rectal cancer
radiation therapy
systemic lupus erythematosus
loop mediated isothermal amplification